title: An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer.
abstract: The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leukocyte A interferon (IFN-alpha 2A), 20 X 10(6) U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN-alpha 2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well-recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN-alpha 2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN-alpha 2A in patients with advanced RCC.
authors.affiliation: Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
authors.forename: E T
authors.initials: ET
authors.lastname: Creagan
authors.forename: J C
authors.initials: JC
authors.lastname: Buckner
authors.forename: R G
authors.initials: RG
authors.lastname: Hahn
authors.forename: R R
authors.initials: RR
authors.lastname: Richardson
authors.forename: D J
authors.initials: DJ
authors.lastname: Schaid
authors.forename: J S
authors.initials: JS
authors.lastname: Kovach
mesh_terms: D000855:Anorexia / Q000139:chemically induced* / Q000188:drug therapy; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004357:Drug Synergism; D005221:Fatigue / Q000139:chemically induced / Q000188:drug therapy; D001068:Feeding and Eating Disorders / Q000139:chemically induced*; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008545:Melanoma / Q000473:pathology / Q000628:therapy; D009220:Myositis / Q000139:chemically induced* / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D007370:Interferon Type I; D001241:Aspirin